Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Aug 2018 Results (n=10) of subset of participants assessing the therapeutic effect of dextromethorphan/quinidine on bulbar motor function published in the British Journal of Clinical Pharmacology
    • 21 Apr 2016 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 21 Apr 2016 Primary endpoint has been met. (Change in Center for Neurologic Study - Bulbar Function Scale (CNS-BFS) Score), as per an abstract presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top